HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KMDA
Kamada Ltd.
KMDA's fundamentals are strong: revenue grew 13% and earnings per share grew 15%, though free cash flow fell 16%. At 21x earnings, it's trading right at its usual valuation. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KMDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
KMDA's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KMDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $5.76 | -29% |
| Forward | 18x | $8.13 | — |
| Fair | 21x | $7.96 | -2.1% |
| Current | 21x | $8.13 | — |
| Expensive | 38x | $14.26 | +75% |
Historical ranges are pointers, not guarantees.
KMDA's PE is in its fair range at 21x. On analysts' estimates for next year's earnings, today's price would be 18x, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KMDA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect KMDA's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KMDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.45 | +18% |
| Q2 2026 | $0.38 | +15% |
| Q1 2026 | $0.35 | +25% |
| Q4 2025 | $0.35 | +40% |
| Q3 2025 | $0.35 | +25% |
| Q2 2025 | $0.33 | +22% |
| Q1 2025 | $0.28 | +22% |
| Q4 2024 | $0.25 | +67% |
| Q3 2024 | $0.28 | +133% |
KMDA has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over KMDA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KMDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $54.9M | +23% |
| Q1 2026 | $45.2M | +2.8% |
| Q4 2025 | $44.7M | +15% |
| Q3 2025 | $47M | +13% |
| Q2 2025 | $44.8M | +5.4% |
| Q1 2025 | $44M | +17% |
| Q4 2024 | $39M | +7.1% |
| Q3 2024 | $41.7M | +10% |
KMDA's revenue has grown year over year for 10 quarters in a row: $55M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 17% | +1.5 points |
| Q1 2026 | 15% | -2.3 points |
| Q4 2025 | 8% | -5.1 points |
| Q3 2025 | 17% | +3.9 points |
| Q2 2025 | 16% | +2.5 points |
| Q1 2025 | 18% | +7 points |
| Q4 2024 | 13% | +5.4 points |
| Q3 2024 | 13% | +1.2 points |
KMDA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KMDA on cash flow, with more consistent year-over-year improvement.
KMDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $16M | +166% |
| Q1 2026 | -$1.3M | +$717K |
| Q4 2025 | $5M | -34% |
| Q3 2025 | $6.8M | -66% |
| Q2 2025 | $6M | -45% |
| Q1 2025 | -$2M | -$319K |
| Q4 2024 | $7.5M | +207% |
| Q3 2024 | $20.1M | +$20.9M |
KMDA generated $26M in free cash flow over the past year, down 16% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KMDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KMDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -1.1M shares |
| 1 year | +2% | +1.1M shares |
| 3 years | +29% | +13.1M shares |
| 5 years | +24% | +11M shares |
| Available history | +39% | +16.3M shares |
KMDA has 58M diluted shares, up 2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q2 2024 | — |
KMDA hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over KMDA on leverage, with a lower net debt burden relative to earnings.
KMDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.9x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
| Q3 2024 | -2.1x | Net Cash |
KMDA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KMDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.1 | Neutral |
| Stochastic | 41.1 | Neutral |
KMDA's weekly RSI is 53 (neutral) and its Stochastic is 41 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KMDA PE vs Healthcare Sector
| Metric | KMDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 17% below |
| PE % | 52 | 29 | 23 pts above |
KMDA is trading at 21x earnings, a 17% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KMDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.96 | 2.1% above |
| 20 week MA | $7.81 | 4.1% above |
| 50 week MA | $7.91 | 2.8% above |
| 100 week MA | $7.44 | 9.3% above |
| 200 week MA | $6.36 | 28% above |
KMDA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KMDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.84 | $6.60 | -3.5% |
| 2021 | $6.60 | $6.78 | +2.7% |
| 2022 | $6.78 | $3.92 | -42% |
| 2023 | $3.92 | $6.12 | +56% |
| 2024 | $6.12 | $5.92 | -3.3% |
| 2025 | $5.92 | $7.07 | +19% |
| 2026 YTD | $7.07 | $8.13 | +15% |
KMDA has the edge over HIMS on returns for 2026, with the stronger performance.